Cozad Asset Management’s Quest Diagnostics DGX Stock Holding History

Cozad Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.26M	Buy	11,529 +1,022	+10%	+$199K	0.18%	127
2025 Q4	$1.82M	Buy	+10,507	New	+$1.91M	0.14%	151
2024 Q1	–	Sell	-10,426	Closed	-$1.44M	–	397
2023 Q4	$1.44M	Sell	10,426 -1,021	-9%	-$134K	0.17%	145
2023 Q3	$1.39M	Sell	11,447 -1,586	-12%	-$211K	0.18%	134
2023 Q2	$1.83M	Sell	13,033 -246	-2%	-$33.9K	0.23%	113
2023 Q1	$1.88M	Sell	13,279 -2,847	-18%	-$407K	0.25%	114
2022 Q4	$2.52M	Buy	16,126 +2,172	+16%	+$312K	0.35%	78
2022 Q3	$1.71M	Buy	+13,954	New	+$1.84M	0.28%	104

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Cozad Asset Management's DGX Position: Q1 2026 in Review

Cozad Asset Management increased its Quest Diagnostics (DGX) stake by 9.7% in Q1 2026, buying an estimated $199K and bringing the position to 11,529 shares worth $2.26M. The position accounts for 0.18% of the portfolio, ranked #127.

Cozad Asset Management first reported a position in DGX in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.52M in Q4 2022. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Cozad Asset Management held 11,529 shares of Quest Diagnostics worth $2.26M as of Q1 2026.
Cozad Asset Management bought 1,022 Quest Diagnostics shares in Q1 2026, an estimated $199K.
Quest Diagnostics made up 0.18% of Cozad Asset Management's portfolio in Q1 2026, its #127 holding.
Cozad Asset Management first reported a position in Quest Diagnostics in Q3 2022 and has held it in 8 quarters since.
Cozad Asset Management's Quest Diagnostics position peaked at $2.52M in Q4 2022.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Cozad Asset Management's 13F filing for Q1 2026, filed 28 May 2026.